Cocrystal Pharma Appoints Biopharma Veteran James Sapirstein as New CEO
Summary
Cocrystal Pharma appointed biopharma veteran James Sapirstein as its new CEO, a key leadership change as the company navigates a "going concern" warning and advances its drug pipeline. The new CEO's compensation includes a significant stock option package.
Key Events
-
New CEO Appointed
James Sapirstein was appointed Chief Executive Officer, effective June 3, 2026. He previously served as CEO of Entero Therapeutics, Inc.
-
Leadership Restructuring
Mr. Sapirstein replaces former Co-Chief Executive Officers Sam Lee and James Martin. Mr. Lee continues as President and Chief Scientific Officer, and Mr. Martin continues as Chief Financial Officer.
-
CEO Compensation Package
The new CEO will receive an annual base salary of $265,000, a 50% target annual performance bonus, and an initial grant of 235,000 stock options exercisable at $1.05 per share. A subsequent grant of an additional 235,000 options is also planned.
Analysis
This 8-K details the appointment of James Sapirstein as the new Chief Executive Officer, a critical leadership change for Cocrystal Pharma, especially given its recent "going concern" warning and active pursuit of capital. Mr. Sapirstein brings significant biopharma experience, which is vital for advancing the company's drug development programs and securing necessary financing. The compensation package, including substantial stock options, reflects the company's effort to attract experienced leadership during a challenging period. This move aims to stabilize the company and drive its strategic initiatives forward.
At the time of this filing, COCP was trading at $0.99 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13.9M. The 52-week trading range was $0.86 to $2.67. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.